Sponsor Deadline
Posted: 3/18/2024

Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

The purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this NOFO as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

ITCR provides support for informatics technology development through four NOFOs aimed at distinct phases of the technology development lifecycle:

  • RFA-CA-24 -016 (R21, Clinical Trial Optional) Supports the development of highly innovative informatics methods and algorithms
  • RFA-CA-24 -017 (this NOFO, U01, Clinical Trial Optional) Supports initial tool development or the significant modification of existing tools for new applications
  • RFA-CA-24 -018 (U24, Clinical Trial Optional) Supports the continued development of emerging informatics technology that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement
  • RFA-CA-24-019 (U24, Clinical Trial Optional) Supports sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources


  • Letter of Intent Due Date: 30 days before the due date
  • Application Due Date(s): June 11, 2024; Nov. 15, 2024

RFA-CA-24-017 Expiration Date November 16, 2024

Amount Description

Budgets are limited to $300,000 Direct Costs (excluding consortium F&A costs) per year.

The maximum project period is three years.